Centessa Pharmaceuticals (CNTA) Competitors $13.61 +0.11 (+0.81%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$13.62 +0.01 (+0.04%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTA vs. BBIO, LEGN, TGTX, TLX, BPMC, SRPT, AXSM, NUVL, VRNA, and GRFSShould you be buying Centessa Pharmaceuticals stock or one of its competitors? The main competitors of Centessa Pharmaceuticals include BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Verona Pharma (VRNA), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry. Centessa Pharmaceuticals vs. BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Verona Pharma Grifols Centessa Pharmaceuticals (NASDAQ:CNTA) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations. Which has more volatility and risk, CNTA or BBIO? Centessa Pharmaceuticals has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Do insiders & institutionals believe in CNTA or BBIO? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are held by institutional investors. 11.6% of Centessa Pharmaceuticals shares are held by insiders. Comparatively, 24.7% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation and earnings, CNTA or BBIO? Centessa Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Centessa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M264.50-$151.09M-$1.99-6.84BridgeBio Pharma$221.90M33.00-$535.76M-$2.85-13.53 Does the media favor CNTA or BBIO? In the previous week, BridgeBio Pharma had 22 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 35 mentions for BridgeBio Pharma and 13 mentions for Centessa Pharmaceuticals. Centessa Pharmaceuticals' average media sentiment score of 1.21 beat BridgeBio Pharma's score of 0.81 indicating that Centessa Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 10 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 14 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in CNTA or BBIO? BridgeBio Pharma received 145 more outperform votes than Centessa Pharmaceuticals when rated by MarketBeat users. Likewise, 72.47% of users gave BridgeBio Pharma an outperform vote while only 60.71% of users gave Centessa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCentessa PharmaceuticalsOutperform Votes3460.71% Underperform Votes2239.29% BridgeBio PharmaOutperform Votes17972.47% Underperform Votes6827.53% Is CNTA or BBIO more profitable? Centessa Pharmaceuticals has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -241.44%. BridgeBio Pharma's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -52.13% -38.01% BridgeBio Pharma -241.44%N/A -75.69% Do analysts prefer CNTA or BBIO? Centessa Pharmaceuticals currently has a consensus target price of $27.71, indicating a potential upside of 103.63%. BridgeBio Pharma has a consensus target price of $57.09, indicating a potential upside of 48.02%. Given Centessa Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 SummaryCentessa Pharmaceuticals beats BridgeBio Pharma on 10 of the 18 factors compared between the two stocks. Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTA vs. The Competition Export to ExcelMetricCentessa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81B$6.85B$5.56B$8.03BDividend YieldN/A2.91%5.07%4.23%P/E Ratio-8.907.5022.7718.87Price / Sales264.50259.05405.66106.84Price / CashN/A65.8538.1834.62Price / Book5.626.566.794.34Net Income-$151.09M$143.63M$3.22B$248.06M7 Day Performance-1.31%3.35%3.36%3.18%1 Month Performance4.21%10.29%6.91%8.28%1 Year Performance43.72%-3.67%16.16%5.04% Centessa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTACentessa Pharmaceuticals2.6315 of 5 stars$13.61+0.8%$27.71+103.6%+42.5%$1.81B$6.85M-8.90200News CoveragePositive NewsGap UpBBIOBridgeBio Pharma4.6164 of 5 stars$33.51-1.1%$53.00+58.2%+39.0%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLEGNLegend Biotech2.7134 of 5 stars$32.24-1.7%$79.00+145.0%-27.8%$5.92B$627.24M-33.941,070Positive NewsTGTXTG Therapeutics3.3281 of 5 stars$36.97-3.5%$40.67+10.0%+164.6%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageGap UpBPMCBlueprint Medicines1.7629 of 5 stars$84.18-0.6%$124.95+48.4%-2.2%$5.38B$508.82M-77.94640Earnings ReportAnalyst ForecastNews CoverageSRPTSarepta Therapeutics4.717 of 5 stars$55.23+2.7%$158.70+187.3%-51.4%$5.36B$1.90B44.18840Upcoming EarningsAXSMAxsome Therapeutics4.8477 of 5 stars$103.00-1.4%$169.80+64.9%+51.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsNUVLNuvalent1.9413 of 5 stars$69.95-2.4%$115.50+65.1%+6.9%$5.01BN/A-20.1640Upcoming EarningsNews CoveragePositive NewsVRNAVerona Pharma2.7514 of 5 stars$60.07+2.0%$75.43+25.6%+361.8%$4.85B$42.28M-31.2930Earnings ReportAnalyst ForecastInsider TradeShort Interest ↓Analyst RevisionNews CoveragePositive NewsGRFSGrifols3.7489 of 5 stars$7.01-1.0%N/A+15.0%$4.82B$7.21B5.9926,300Short Interest ↓Positive News Related Companies and Tools Related Companies BBIO Alternatives LEGN Alternatives TGTX Alternatives TLX Alternatives BPMC Alternatives SRPT Alternatives AXSM Alternatives NUVL Alternatives VRNA Alternatives GRFS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTA) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTA Stock Free CNTA Stock Alerts